BeOne Medicines enters July with short sellers voting heavily with their feet — and the borrow market confirming there's almost no conviction left on the bearish side.
Short interest has collapsed over the past month, the clearest structural story in the data right now. Shorts outstanding fell roughly 27% over the past 30 days to just 0.73% of the free float — a level so thin it barely registers as a meaningful opposing force. The week's move alone was a 24.6% decline in shares short. With borrow availability at over 5,100% — meaning there are more than fifty shares available to lend for every one currently borrowed — there is no scarcity-driven squeeze dynamic in play. Cost to borrow runs at just 0.53%, barely above a general collateral rate, confirming that no one is paying a premium to establish or maintain a short position. The ORTEX short score has drifted down to 31.9 this week from 36.1 ten days ago, tracking the reduction in short positioning almost precisely.
Options positioning has also rotated since mid-June, and the shift is notable. The put/call ratio declined to 0.79, its lowest reading of the past year — well below the 52-week high of 2.04 reached earlier in the window. That's a reversal from a sustained bearish options lean: as recently as mid-May, the PCR ran above 1.15 for weeks. At 0.54 standard deviations below the 20-day mean of 0.90, the current setup reflects a market tilting incrementally toward calls rather than puts. Combined with the short retreat, positioning has rotated from cautious to mildly constructive.
The Street backs that rotation with near-unanimous bullish conviction. Nearly every covering analyst carries an Outperform, Overweight, or Buy rating, with the mean price target at $412 against a close of $284.97 — implying roughly 45% upside. RBC Capital raised its target to $436 in early June. Barclays, Guggenheim, and Truist all lifted targets following the May earnings print, which delivered a 6.6% next-day gain. Wells Fargo initiated at Overweight with a $400 target in early May, and Wolfe Research launched coverage at Outperform in late March. The sole dissent comes from Jefferies, which downgraded to Hold with a $290 target in March — a call that currently sits almost exactly at the current share price, making it the closest to the money of any on the Street. EPS surprise ranks in the 93rd percentile against the broader universe, and both 30-day and 90-day EPS momentum scores are strong at 80 and 88 respectively, suggesting estimates have been moving in the right direction.
Valuation is where the bull case requires the most faith. The PE multiple is running at 33.5x on a trailing basis, compressing about 6 points over the past 30 days. EV/EBITDA at 22.6x has also eased slightly. The bear case — as articulated by the company's own risk framework — centres on slower Brukinsa uptake, pipeline failures, and geopolitical exposure given the company's China operations. The bull case rests on Brukinsa reaching peak sales of roughly $7.1 billion by 2034, with sonrotoclax adding another $3.4 billion on top. Those are long-dated projections, and the stock is partly being priced on their credibility.
One detail worth flagging is the insider activity. Every transaction recorded over the past month has been a sale — the founder and CEO, President/COO, CFO, General Counsel, and Principal Accounting Officer all sold shares in June. The transactions appear spread across routine exercise-and-sell patterns rather than a single concentrated exit, and none carries a high significance score. Still, the direction is consistently one-way, with net insider activity showing sellers across the C-suite. Against the backdrop of analyst optimism and retreating shorts, that persistent insider selling is the one thread that runs counter to the prevailing narrative.
The next scheduled earnings print is August 27. Between now and then, the primary variable to watch is whether Brukinsa commercial momentum data — referenced in analyst updates — continues to track ahead of consensus, or whether the Jefferies Hold thesis starts attracting company at the $290 level.
See the live data behind this article on ORTEX.
Open ONC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
